An engineered in-house nanoluciferase-based immunoassay was used to quantify ecto-GPR37 in CSF samples from neurological control (NC) subjects, PD patients and Alzheimer’s disease (AD) patients. The gene discussed is GPR37; the disease is early-onset autosomal dominant Alzheimer disease.